2PU Stock Chart & Stats
€1.41
€0.08(6.19%)
At close: 4:00 PM EDT
€1.41
€0.08(6.19%)
Day’s Range― - ―
52-Week Range€0.87 - €4.22
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.11M
Enterprise Value€4.31M
Total Cash (Recent Filing)€2.17M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding3,652,285
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.14
Price to Sales (P/S)0.00
P/FCF Ratio-1.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.9
Revenue Forecast (FY)€13.95M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of reported debt reduces interest expense and refinancing pressure, giving Pulmatrix more flexibility while it advances development programs. Although the company remains financially constrained, avoiding leverage limits one source of downside and preserves potential financing capacity.
Improved Cash BurnThe substantial reduction in operating cash burn indicates better cost control than in earlier periods and could extend the company’s operating runway. This improvement does not eliminate funding needs, but it may support more disciplined allocation toward clinical development and partnerships.
Proprietary Respiratory PlatformA proprietary pulmonary delivery technology gives Pulmatrix a focused platform around respiratory disease applications rather than a single undifferentiated candidate. If development succeeds, the platform could support multiple indications and create partnering or commercialization opportunities.
Bears Say
Revenue Has Collapsed To ZeroThe lack of a current revenue base means Pulmatrix has not yet demonstrated commercial traction or recurring operating income. Over the next several quarters, value creation therefore remains dependent on clinical progress, partnering, or future commercialization rather than an established business.
Persistent Losses And Cash ConsumptionOngoing net losses and negative operating and free cash flow show that the business is still consuming capital to operate. Without positive cash generation, Pulmatrix may need continued external funding, which can constrain development plans and increase financial dependence.
Shrinking Financial CushionThe steep decline in stockholders’ equity reflects cumulative losses and leaves a materially smaller balance-sheet cushion than in 2021. Reduced equity can limit resilience during prolonged development cycles and make future financing more consequential for existing stakeholders.
Pulmatrix News
2PU FAQ
What was Pulmatrix’s price range in the past 12 months?
Pulmatrix lowest stock price was €0.87 and its highest was €4.21 in the past 12 months.
What is Pulmatrix’s market cap?
Pulmatrix’s market cap is €5.11M.
When is Pulmatrix’s upcoming earnings report date?
Pulmatrix’s upcoming earnings report date is Nov 05, 2026 which is in 31 days.
How were Pulmatrix’s earnings last quarter?
Pulmatrix released its earnings results on Aug 13, 2026. The company reported -€0.256 earnings per share for the quarter.
Is Pulmatrix overvalued?
According to Wall Street analysts Pulmatrix’s price is currently Overvalued.
Does Pulmatrix pay dividends?
Pulmatrix does not currently pay dividends.
What is Pulmatrix’s EPS estimate?
Pulmatrix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pulmatrix have?
Pulmatrix has 3,652,285 shares outstanding.
What happened to Pulmatrix’s price movement after its last earnings report?
Pulmatrix reported an EPS of -€0.256 in its last earnings report. Following the earnings report the stock price went up 0.162%.
Which hedge fund is a major shareholder of Pulmatrix?
Currently, no hedge funds are holding shares in DE:2PU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pulmatrix
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.